Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Apogee Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Apogee Therapeutics, Inc.

APGE

Apogee Therapeutics, Inc.

About Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc. is a clinical-stage biotechnology company developing novel biologic therapies for inflammatory and immunology (I&I) diseases such as atopic dermatitis, asthma, eosinophilic esophagitis, and COPD. Its pipeline features engineered monoclonal antibodies with extended half-life modifications targeting IL-13, OX40L, TSLP, and IL-4Rα. Apogee aims to improve efficacy and reduce dosing frequency, addressing unmet needs through optimized antibody design and combination therapies.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Apogee Therapeutics, Inc.

1
1
Apogee Therapeutics, Inc. Apogee Therapeutics Reports $74.1 Million Net Loss and Significant Cash Increase for Q1 2026

Via official filing (AI summary) | 25 days ago | 0 comments

2
1
Apogee Therapeutics, Inc. Apogee Therapeutics Reports $255.8M Net Loss and Clinical Trial Progress in Annual Filing

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Apogee Therapeutics, Inc. Apogee Therapeutics Reports $65M Net Loss in Q3 2025, Increases R&D Spending

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Apogee Therapeutics, Inc. Apogee Therapeutics Reports $66.1 Million Net Loss in Q2 2025 Amid Increased R&D Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Apogee Therapeutics, Inc. Apogee Therapeutics Reports Increased Operating Expenses and Net Loss for Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Apogee Therapeutics, Inc. Apogee Therapeutics Reports $182.1 Million Net Loss for Year Ended December 31, 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Apogee Therapeutics, Inc. Apogee Therapeutics Reports Significant Financial Developments, Increased Expenses, and Net Losses

Via official filing (AI summary) | over 1 year ago | 0 comments